Skip to main content
Premium Trial:

Request an Annual Quote

IP Services Firm Files for Reexamination of Abbott Multiplex PCR Patent

NEW YORK (GenomeWeb News) – Troll Busters, an intellectual property services firm that specializes in challenging the validity or claims of certain patents, today announced that it has filed a brief with the US Patent and Trademark Office for reexamination of a patent covering multiplex PCR-based diagnostics.
The patent at issue, No. 5,582,989, is entitled “Multiplex genomic DNA amplification for deletion detection,” and covers a method for detecting multiple DNA sequences simultaneously. Multiplex, PCR-based genetic tests may fall under the broad-based claims of the patent.
Baylor College of Medicine is listed as the assignee of the patent, which was granted in December 1996. The patent is exclusively licensed to Abbott Laboratories.
The claims in the patent “are overly broad,” Jeff Oster, founder of Troll Busters, told GenomeWeb Daily News. “There is prior art, there’s new prior art that was not considered during the US application, and the US file history had a lot of flaws in it,” he added.
Oster said the USPTO generally takes around three months to decide whether or not it will reexamine the patent.
He said the reexamination brief should be available on the USPTO website next week.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.